J & J's financial position is strong and its debt is low<br>The pharmaceutical business of JNJ (accounting for 54% of sales) will continue to show the clearest<br>Prospects, derived from existing major drugs (e.g. stelara, imbruvica<br>Darzalex) has a strong prospect, and the drugs under development perform well<br>Fourteen new drugs are expected to be launched by the end of 2023<br>JNJ is studying novel coronavirus pneumonia vaccine, which is expected to be available in the first quarter of 2021.<br>The world. If the vaccine is first launched on the market, JNJ will get a lot of money<br>Business benefits<br>
正在翻译中..